Overview

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

Status:
Completed

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and the best dose of carfilzomib in treating patients with relapsed or refractory chronic lymphocytic leukemia(CLL),small lymphocytic lymphoma(SLL), or prolymphocytic leukemia (PLL).

Phase:

Phase 1

Details

Lead Sponsor:

Ohio State University Comprehensive Cancer Center

Collaborators:

Amgen
Onyx Pharmaceuticals